{"paper_id":"2318827f-47d9-439f-8570-d9ea2500144a","body_text":"Abstract\nEstrogen plays a role in the pathogenesis of endometriosis. The CYP17 gene codes for the cytochrome P450c17α enzyme that is involved in the estrogen biosynthesis. We aimed to investigate if CYP17 polymorphism could be used as marker to predict the susceptibility of endometriosis. Women were divided into two groups: (1) severe endometriosis (n=119); (2) non-endometriosis groups (n=128). A 169-bp fragment encompassing the T/C polymorphic site in 5′-untranslated promoter region (5′-UTR) of the CYP17 was amplified by the polymerase chain reaction, treated with restriction enzyme MspA1I, and electrophoresis. The polymorphism was divided into restriction-enzyme indigestible (T homozygote), T/C heterozygote, and digestible (C homozygote). Genotypes and allelic frequencies for this polymorphism in both groups were compared. We observed a higher but non-significant percentage of T homozygote in the endometriosis women compared with the non-endometriosis women. Proportions of T homozygote/heterozygote/C homozygote for CYP17 in both groups were: (1) 26.1/46.2/27.7% and (2) 17.2/45.3/37.5% (p-value=0.131). T allele was related with higher susceptibility of endometriosis. T and C allele frequencies in both groups were: (1) 49.2/50.8%; (2) 39.8/60.2% (p-value=0.046). Despite the CYP17* T allele appearing to be asscoiatd with a trend of increased risk of endometriosis, CYP17 5′-UTR gene polymorphism might not be a useful marker for prediction of endometriosis susceptibility.\nSimilar content being viewed by others\nReferences\nHadfield R.M. Mardon H.J, Barlow D.H, Kennedy S. 1997 Endometriosis in monozygotic twins.Fertil. Steril. 68, 941–942.\nSano M, Inoue S, Hosoi T, Ouchi Y, Emi M, Shiraki M,et al. 1995 Association of estrogen receptor dinucleotide repeat polymorphism with osteeoporosis.Biochem. Biophys. Res. Commun. 217, 378–383.\nKennedy S. The genetics of endometriosis. 1998J Reprod. Med. 43, 263–268.\nDunning A. M., Healey C. S., Pharoah P. D., Teare M. D., Ponder B. A., Easton D. F. 1999 A systematic review of genetic polymorphisms and breast cancer risk.Cancer. Epidemiol. Biomarkers. Prev. 8, 843–854.\nCarey A. H., Waterworth D., Patel K., White D., Little J., Novelli P, Franks S, Williamson R. 1994 Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17.Hum. Mol. Genet. 3, 1873–1876.\nHabuchi T, Liqing Z, Suzuki T, Sasaki R, Tsuchiya N, Tachiki H, Shimoda N, Satoh S, Sato K, Kakehi Y, Kamoto T, Ogawa O, Kato T. 2000 Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.Cancer Res. 60, 5710–5713.\nPicado-Leonard J. and Miller W. L. 1987 Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/ 17,20 lyase): similarity with the gene for P450c21.DNA 6 439–448\nHsieh Y, Chang C, Tsai F, Wu J, Tsai C, Tsai H. 2001a Androgen receptor trinucleotide polymorphism in endometriosis.Fertil Steril. 76 412–413.\nChang C.C, Hsieh Y.Y, Wu J.Y, Tsai F.J, Lin C.C, Tsai CH. Yeh LS. Estrogen receptor dinucleotide repeat polymorphism in Taiwan Chinese with endometriosis.J Assist. Reprod. Genet. in press.\nChang C. C., Hsieh Y. Y., Tsai F. J., Tsai C. H., Tsai H. D., Lin C. C. 2002 The proline form of p53 codon 72 polymorphism is associated with endometriosis.Fertil. Steril. 77, 43–45.\nHsieh Y. Y., Tsai F. J., Chang C. C., Chen W. C., Tsai C. H., Tsai H. D., Lin C. C. 2001b p21 gene codon 31 arginine/serine polymorphism: non-association with endometriosis.J Clin. Lab. Anal. 15, 184–187.\nHsieh Y. Y., Chang C. C., Tsai F. J., Hsu Y., Tsai H. D., Tsai C. H. 2002 Polymorphisms for interleukin-4 (IL-4) -590 promoter, IL-4 intron3, and tumor necrosis factor alpha -308 promoter: Non-association with endometriosis.J Clin. Lab. Anal. 16, 121–126.\nMartucci C. P. and Fishman J. 1993 P450 enzymes of estrogen metabolism.Pharmacol. Ther. 57 23–57\nFeigelson H. S., Coetzee G. A., Kolonel L. N., Ross R. K., Henderson B. E. 1997 A polymorphism in the CYP17 gene increases the risk of breast cancer.Cancer Res. 57, 1063–1065.\nBergman-Jungestrom M, Gentile M, Lundin A.C, Wingren S. 1999 Association between CYP17 gene polymorphism and risk of breast cancer in young women.Int. J. Cancer 84, 350–353.\nYoung I. E., Kurian K. M., Annink C, Kunkler IH, Anderson VA, Cohen BB, Hooper ML, Wyllie AH, Steel CM. 1999 A polymorphism in the CYP17 gene is associated with male breast cancer.BrJ Cancer 81, 141–143.\nFeigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE, 1998 Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations.Cancer Res 58, 585–587.\nHaiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT, Hunter DJ. 1999 The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.Cancer Res 59, 1015–1020.\nDiamanti-Kandarakis E, Bartzis MI, Zapanti ED, Spina GG, Filandra FA, Tsianateli TC, Bergiele AT, Kouli CR. 1999 Polymorphism T>C (-34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome.Fertil Steril 71, 431–435.\nHaiman CA, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I. 2001 A polymorphism in CYP17 and endometrial cancer risk.Cancer Res 61, 3955–3960.\nNedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lonning PE, Erikstein B, Karesen R, Gabrielsen OS, Borresen-Dale AL. 1999 CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1.Cancer Res 59, 2825–2828.\nWeston A, Pan CF, Bleiweiss IJ, Ksieski HB, Roy N, Maloney N, Wolff MS. 1998 CYP17 genotype and breast cancer risk.Cancer Epidemiol Biomarkers Prev 7 941–944\nHelzlsouer KJ, Huang HY, Strickland PT, Hoffman S, Alberg AJ, Comstock GW, Bell DA. 1998 Association between CYP17 polymorphisms and the development of breast cancer.Cancer Epidemiol Biomarkers Prev 7, 945–949.\nTechatraisak K, Conway GS, Rumsby G. 1997 Frequency of a polymorphism in the regulatory region of the 17 alpha-hydroxylase-17,20-lyase (CYP17) gene in hyperandrogenic states.Clin Endocrinol (Oxf) 46, 131–134.\nDunning AM, Healey CS, Pharoah PD, Foster NA, Lipscombe JM, Redman KL, Easton DF, Day NE, Ponder BA. 1998 No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer.Br J Cancer 77, 2045–2047.\nLunn RM, Bell DA, Mohler JL, Taylor JA. 1999 Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).Carcinogenesis 20 1727–1731.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nHsieh, YY., Chang, CC., Tsai, FJ. et al. Cytochrome P450c17α 5′-untranslated region *T/C polymorphism in endometriosis. J Genet 83, 189–192 (2004). https://doi.org/10.1007/BF02729896\nReceived:\nRevised:\nIssue date:\nDOI: https://doi.org/10.1007/BF02729896","source_license":"public-domain-us","license_restricted":false}